The following information is exclusively reserved for physicians practicing in Austria, the Netherlands, Spain, and Switzerland where the Zio™ monitor ECG monitoring service is currently authorised and made available for use in accordance with local regulatory requirements.

Learn more
Search

The Zio™ monitor

Precision in cardiac monitoring begins here.

iRhythm's thinnest and lightest long-term continuous monitor (LTCM)1 is at the heart of the iRhythm monitoring service.

Learn how to use
Zio monitor

Precisely what patients need

Our latest generation Zio monitor is smaller1 and comfortable2,3,5 so patients can go about their daily activities, including sleeping, showering, and exercising.2,3,5 The Zio monitor drives high patient compliance,2,3,5 ensuring continuous, uninterrupted ECG recording, resulting in a comprehensive end-of-wear report.4-6

Easy

Patient-centric design makes it simple to apply and wear2

Convenient

Breathable,7-8 pliable,2-4 and waterproof housing7-8 made for patients' every day2-4

Accurate

The iRhythm monitoring service utilizes advanced CE-marked and FDA-cleared AI with the only deep-learned algorithm* clinically proven to be as accurate as expert cardiologists9-12
Patient wearing Zio monitor

Exceptional accuracy for extraordinary results

The iRhythm monitoring service, featuring Zio ECG monitors, provides highly accurate data you can trust and helps you make the right diagnosis the first time.1,6,13

  • 99% patient compliance with prescribed wear times4-6
  • Highest yield of specified arrhythmia diagnosis compared to all other monitoring services5-6,13-19
  • Lowest likelihood of repeat testing compared to all other monitoring services5-6,13-19
  • End-of-wear reports with 99% physician agreement5-6,20

Get started with an end-to-end service

The iRhythm monitoring service incorporates leading technology and tools at each step of the cardiac monitoring experience.

Artificial intelligence graphic

Advanced AI

We combine a deep-learned CE-marked and FDA-cleared algorithm* with Qualified ECG Specialists (QES)9-12 to generate end of wear reports with 99% physician agreement.5-6,20
Learn more
iRhythm ZioSuite on a laptop

ZioSuite™ portal

Interpret reports, manage patients, and more - from the computer.
Learn more
Zio monitor

Zio monitor IFU

Learn how to apply and use the Zio monitor.

View Instructions for Use

Continue the conversation

The Zio™ service helps you detect arrhythmias earlier, reduce administrative burden, and enhance patient experience — all through a single, streamlined platform.

 

Connect with an iRhythm specialist today to discover how the Zio™ Service can fit into your workflow.

Continue the conversation
Man with child on his shoulders
  1. Data on file. iRhythm Technologies, 2023. 
  2. Zio monitor Instructions for Use. iRhythm Technologies, 2023. 
  3. Battisti et al. Abstract 4141717: Feasibility of point-of-wear patient satisfaction surveys to validate patient-centered product enhancements: results from over 300,000 patients for long-term ambulatory cardiac monitoring. Circulation. 2024;150:A4141717. doi:10.1161/circ.150.suppl_1.4141717. https://www.ahajournals.org/doi/abs/10.1161/circ.150.suppl_1.4141717 
  4. Data on file. iRhythm Technologies, 2022. 
  5. Based on the US data. 
  6. Zio service provides continuous, uninterrupted recording and a comprehensive end-of-wear report. 
  7. Data on file. iRhythm Technologies, 2017, 2023. 
  8. The Zio monitor device should not be submerged in water. During a bath, keep the device above water. Please refer to the Zio monitor labeling instructions or Patient Guide for the full set of details. 
  9. Data on file. iRhythm Technologies, 2020. 
  10. Hannun et al. Cardiologist-level arrhythmia detection and classification in ambulatory electrocardiograms using a deep neural network. Nat Med. 2019;25:65-69.https://doi.org/10.1038/s41591-018-0268-3 
  11. Deep learned algorithm is only available in the United States, European Union, Switzerland, United Kingdom, and Japan.  
  12. FDA 510K clearance, CE mark, UKCA mark, and PMDA-approval. 
  13. Based on the US market data using Zio ECG monitors. 
  14. Reynolds et al. Comparative effectiveness and healthcare utilization for ambulatory cardiac monitoring strategies in Medicare beneficiaries. Am Heart J. 2024;269:25–34. https://doi.org/10.1016/j.ahj.2023.12.002
  15. Diagnostic yield was assessed based upon the evaluation of specified arrhythmias, which refer to an arrhythmia encounter diagnosis as per Hierarchical Condition Categories (HCC) 96. 
  16. Based on previous generation Zio XT device data. Zio monitor utilizes the same operating principles and ECG algorithm. Additional data on file. 
  17. Zio LTCM service refers to Zio XT and Zio monitor service.  
  18. Contraindications: Do not use the Zio monitor for critical care patients or for patients with symptomatic episodes where instance variations in cardiac performance could result in immediate danger to the patients or when real-time or in-patient monitoring should be prescribed. (Refer to the Zio monitor Instructions for Use for the full list of contraindications.) 
  19. Zio monitor and ZEUS are CE-marked.  
  20. 99% of physicians agree with the comprehensive end-of-wear report. Based on a review of all online Zio XT, Zio monitor, and Zio AT end-of-wear reports. Data on file. iRhythm Technologies, 2023.

 

*ZioTM ECG Utilization Service (ZEUS) System

 

The Zio™ service is a long-term continuous ambulatory cardiac monitoring service. It consists of the Zio™ monitor that collects beat-to-beat ECG data and can be worn for up to 14 days; the Zio™ ECG Utilization Service (ZEUS) System deep learned algorithm, which detects arrhythmias. The data is reviewed and curated by a team of Qualified ECG Specialists (QES) to provide the final patient report.

 

For indications for use, warnings & contraindications, visit here.

 

iRhythm, Zio, Zio monitor and ZioSuite are trademarks of iRhythm Technologies, Inc. ©2024 All rights reserved.

 

Zio™ monitor and ZEUS are CE-marked (CE2797).

 

Zio monitor, ZEUS and Zio service are currently available in Austria, Netherlands, Spain & Switzerland.

 

For further regulatory information visit here.

WEB0208.01